Responses
Other responses
Jump to comment:
- Published on: 6 October 2003
- Published on: 27 June 2003
- Published on: 20 February 2003
- Published on: 6 February 2003
- Published on: 28 January 2003
- Published on: 7 January 2003
- Published on: 6 October 2003Is Cochrane not in the archives?Show More
Dear Editor
There is one reason why I was initally interested to read the systematic review of intravenous immunoglobulin in haemolytic diseases of the newborn [1] and then concerned by the published responses.
Neither the authors of the systematic review published in Archives nor the respondents to that article cited or discussed the 2002 Cochrane systematic review on exactly the same neonatal topic...
Conflict of Interest:
None declared. - Published on: 27 June 2003Reply to Ovaly and ClearyShow More
Dear Editor
We are grateful to our colleagues for their interest and responses to our paper.[1] In response to Dr Ovaly’s comments we agree that late anaemia can be a problem in these babies who receive intravenous immunoglobulin (IVIG), as also demonstrated in our systematic review. Even when infants have received exchange transfusions (XTs) top-up red cell transfusions may be required. In a recent local audit of XTs, 3...
Conflict of Interest:
None declared. - Published on: 20 February 2003Systematic review of intravenous immunoglobulin in haemolytic disease of the newborn.Show More
Dear Editor
We read with interest the recent review of Gottstein and Cooke.[1]
Their systematic review of trials reporting treatment of infants with proven Rh and/or ABO haemolytic disease of the newborn (HDN) treated with high dose intravenous immunoglobulin (HDIVIG) and phototherapy with phototherapy alone demonstrated that significantly fewer infants required exchange transfusion in the HDIVIG group. The...
Conflict of Interest:
None declared. - Published on: 6 February 2003Late anemia in Rh hemolytic diseaseShow More
Dear Editor
As it is clearly stated in the review by Gottstein and Cooke,[1] we consider it unethical to withhold or delay high dose intravenous immunglobulin (IVIG) treatment in infants with haemolytic disease of the newborn. Since the study we have done in 1995,[2] we have treated 129 patients with Coombs positive hemolytic disease of the newborn, with the same method and had to resort to exchange transfusio...
Conflict of Interest:
None declared. - Published on: 28 January 2003High dose IVIG in hemolytic disease of neonatesShow More
Dear Editor
It has been encouraging to read article of Gottstein et al.[1] on use of high dose Intravenous Immunoglobulin (HDIVIG), in case of hemolytic disease of newborns (HDN) & the conclusion showing effectiveness of HDIVIG. I have following observations to make with respect to implication to practice & future research. All the references mentioned [2-6] were 3-10 years old. These trials have n...
Conflict of Interest:
None declared. - Published on: 7 January 2003IV immunoglobulin in haemolytic disaese of the newbornShow More
Dear Editor
The systematic review of intravenous immunoglobulin (ivIgG) in haemolytic disease of the newborn (HDN) by Gottstein and Cooke[1] raises some interesting points. The first fascinating observation is just how tiny is the number of babes, worldwide, entered into published randomised (or quasi-randomised) studies suitable for this sort of systematic review.
I too was struck by the apparently un...
Conflict of Interest:
None declared.